Login
$FATE
$1.13 -$0.01 (0.82%) After hours

$FATE 8-K SEC Filings

Filed On Filing
05 Nov 2026 8-K: Entry into a Material Definitive Agreement; Termination of a Material Definitive Agreement

Fate Therapeutics, Inc., a Delaware corporation (the “Company”), confirms its agreement (this “Agreement”) with Leerink Partners LLC (the “Agent”), as follows:

05 Nov 2026 8-K: Results of Operations and Financial Condition

Safety profile presented at ASN Kidney Week 2026 across 29 autoimmune patients treated with a single dose of FT819 and fludarabine-free, less-intensive conditioning continues to be favorable, further supporting RECLAIM-LN

28 Sep 2026 8-K: Other Events

Fate Therapeutics Announces Receipt of California Institute for Regenerative Medicine (CIRM) CLIN2 Grant to Advance RECLAIM-LN

13 Aug 2026 8-K: Results of Operations and Financial Condition

First lupus nephritis patient dosed in RECLAIM-LN, a Phase 2 potentially registrational trial utilizing FT819, an iPSC-derived, off-the-shelf CAR T-cell therapy; patient was treated as an outpatient with same-day discharge

15 Jun 2026 8-K: Departure/Election of Directors or Officers; Compensation; Submission of Matters to a Vote of Security Holders

The name of the plan is the Fate Therapeutics, Inc. Third Amended and Restated 2022 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Cons...

04 Jun 2026 8-K: Other Events

TRANSFORMING THE LIVES OF PATIENTS LIV ING WITH AUTOIMMUN E DISEASES AND C ANCER Making Cell Therapies Accessible to AllTM CORPORATE PRESENTATION June 2026 | NASDAQ: FATE | Non-Confidential © 2026 Fate Therapeutics. All rights reserved

13 May 2026 8-K: Results of Operations and Financial Condition

RECLAIM – LN, a Phase 2 potentially registrational clinical trial of FT819 in patients with refractory moderate-to-severe systemic lupus erythematosus (SLE) with lupus nephritis, on schedule to initiate in the 2nd half of 2026

26 Feb 2026 8-K: Results of Operations and Financial Condition

Outpatient treatment enabled under FT819-102 autoimmune basket protocol with patients now treated with FT819 off-the-shelf CAR T-cell therapy as same-day hospital discharge

13 Nov 2025 8-K: Results of Operations and Financial Condition

Authorization Received from UK and EU Authorities to Activate ex-US Clinical Trial Sites Supporting the Ongoing Patient Enrollment of FT819, an Off-the-Shelf CD19-targeted CAR T-cell Product Candidate that Utilizes Less-intensive or No C...

27 Oct 2025 8-K: Regulation FD Disclosure; Other Events

Fate Therapeutics Presents New Clinical Data at ACR Convergence 2025 Demonstrating Immune Remodeling and Durable Responses in Patients with Systemic Lupus Erythematosus Treated with FT819 Off-the-Shelf CAR T-Cell Therapy

14 Oct 2025 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Fate Therapeutics, Inc. (“Fate” or the “Company”) is pleased to offer you an exempt full-time position as Chief Financial Officer, reporting to the Company’s President & Chief Executive Officer. This position has an anticipated start dat...

12 Aug 2025 8-K: Results of Operations and Financial Condition; Costs Associated with Exit or Disposal Activities

First patient treated with FT819 off-the-shelf CAR T-cell product candidate following fludarabine-free conditioning for severe lupus nephritis demonstrated durability of response with drug-free definition of remission in systemic lupus e...

30 May 2025 8-K: Departure/Election of Directors or Officers; Compensation; Amendments to Articles/Bylaws; Change in Fiscal Year +2 more

The name of the plan is the Fate Therapeutics, Inc. Second Amended and Restated 2022 Stock Option and Incentive Plan (the “Plan”). The purpose of the Plan is to encourage and enable the officers, employees, Non-Employee Directors and Con...

13 May 2025 8-K: Results of Operations and Financial Condition

Additional Phase 1 Data for FT819 Off-the-Shelf CAR T-cell Product Candidate in Moderate-to-Severe Systemic Lupus Erythematosus to be Featured in Oral Presentation at EULAR 2025 Congress in June

05 Mar 2025 8-K: Results of Operations and Financial Condition

Phase 1 Dose Expansion Initiated for FT819 Off-the-Shelf CAR T-cell Product Candidate with Fludarabine-free Conditioning in Moderate-to-Severe SLE

06 Jan 2025 8-K: Departure/Election of Directors or Officers; Compensation

Effective January 1, 2025 (the “Start Date”), J. Scott Wolchko (“Advisor”) and Fate Therapeutics, Inc. (“Company”) agree as follows pursuant to the instant agreement (“Advisory Agreement” or “Agreement”):

29 Nov 2024 8-K: Departure/Election of Directors or Officers; Compensation; Regulation FD Disclosure

Bob Valamehr, Ph.D. MBA, To Become President and CEO January 1, 2025

12 Nov 2024 8-K: Results of Operations and Financial Condition

Initial Clinical Data from Phase 1 Autoimmunity Study of FT819 1XX CAR T-cell Product Candidate to be Presented in 4Q24; Second Treatment Arm Adding FT819 to Maintenance Therapy without Conditioning Chemotherapy Opened for Enrollment

30 Aug 2024 8-K: Entry into a Material Definitive Agreement; Departure/Election of Directors or Officers; Compensation

This [Amended and Restated] Indemnification Agreement (“Agreement”) is made as of [________, 20__], by and between Fate Therapeutics, Inc., a Delaware corporation (the “Company”), and (“Indemnitee”).

13 Aug 2024 8-K: Results of Operations and Financial Condition

Enrollment Ongoing with FT819 1XX CAR T-cell Product Candidate in Phase 1 Autoimmunity Study; Single-agent Cyclophosphamide Included as Alternative Conditioning Regimen

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Create Account

Sign up for free to unlock this feature.

Already have an account? Sign in

Premium Feature

This feature requires a premium subscription to unlock unlimited historical data and advanced analysis tools.

Premium includes:

  • Unlimited historical financial data
  • Advanced analytics and insights
  • Priority support